Pipeline news

• Marinus Pharmaceuticals Announces FDA Approval of ZTALMY® (ganaxolone) for CDKL5 Deficiency Disorder

  18 March 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved ZTALMY^® (ganaxolone) oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder (CDD), a rare form of genetic epilepsy, in patients two years of age and older.¹ ZTALMY, the first FDA approved treatment specifically in CDD, is a neuroactive steroid that acts as a positive allosteric modulator of the GABA_A receptor. It is expected to be available through a designated specialty pharmacy in July 2022.

• binx health Appoints Industry Veteran Todd Bennett as Chief Commercial Officer

  16 March 2022

  

  binx health , a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Todd Bennett as Chief Commercial Officer (CCO). Bennett is an accomplished industry veteran, having held multiple executive leadership roles at several high-growth companies including Luminex, Immucor, Roche and Abbott.

• binx health Announces Appointment of UnitedHealth Group’s Optum Rx Chief Financial Officer Jeff Grosklags to its Board of Directors

  04 March 2022

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study, and shop, announced today the appointment of Jeff Grosklags, an accomplished industry leader and UnitedHealth Group’s Optum Rx Chief Financial Officer (CFO) to its Board of Directors. For the past 16 years, Grosklags has worked in a financial leadership capacity within Optum and UnitedHealth Group.

• Epic Sciences and Fulgent Genetics Collaborate to Deliver Definembc™ Results for Metastatic Breast Cancer Patients

  24 February 2022

  

  Epic Sciences, Inc. today announced it has partnered with Fulgent Genetics (NASDAQ:FLGT) to deliver DefineMBC comprehensive profiling results for metastatic breast cancer (MBC) patients. The partnership links Fulgent’s leading CAP/CLIA certified Next Generation Sequencing services with Epic’s best-in-class cell analysis platform as part of Epic’s novel DefineMBC liquid biopsy test.

• Marinus Pharmaceuticals Announces Delay to RAISE Phase 3 Clinical Trial in Status Epilepticus and Associated IV Ganaxolone Clinical Trials

  23 February 2022

  

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the RAISE, Phase 3, double-blind placebo-controlled trial for the treatment of status epilepticus, is now expected to be completed in the second half of 2023.

• binx health and North Dakota Department of Public Health Partner to Combat the Spread of Sexually Transmitted Infections

  15 February 2022

  

  binx health, a healthcare technology and diagnostics company that makes routine testing convenient, and the North Dakota Department of Health (NDDoH) are working together to combat the spread and support the treatment of sexually transmitted infections (STIs).

• Marinus Pharmaceuticals Completes In Vivo M2 Metabolite Study and Provides European Regulatory Update

  04 February 2022

  

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced preliminary results from an in vivo study on the M2 metabolite showing that no genotoxicity was found, as measured by formation of micronuclei in the bone marrow or comet morphology in the liver.

• Epic Sciences and Biosplice Therapeutics Announce Partnership for Metastatic Cancer Trials

  30 January 2022

  

  Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and Epic Sciences, Inc., a leading liquid biopsy diagnostic company, announce they are collaborating to incorporate multi-omic profiling in Biosplice’s clinical oncology programs, including Cirtuvivint (SM08502).

• Epic Sciences Unveils Definembc™, a Novel Blood-Based Test Designed to Improve Care for Metastatic Breast Cancer Patients

  16 December 2021

  

  Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available.

• Epic Sciences Platform Demonstrates Compelling Value of Cell Analysis in Data Presented at San Antonio Breast Cancer Symposium 2021

  15 December 2021

  

  Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate.